Home Crystal structure of N-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioamide, C21H29N3S
Article Open Access

Crystal structure of N-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioamide, C21H29N3S

  • Ebtehal S. Al-Abdullah , Hazem A. Ghabbour , Hamad M. Alkahtani , Abdul-Malek S. Al-Tamimi and Ali A. El-Emam EMAIL logo
Published/Copyright: May 19, 2016
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Zeitschrift für Kristallographie - New Crystal Structures
From the journal Zeitschrift für Kristallographie - New Crystal Structures Volume 231 Issue 3

Abstract

C21H29N3S, orthorhombic, Pbca (No. 61), a = 9.8658(7) Å, b = 11.7298(9) Å, c = 31.960(2) Å, V = 3698.5(5) Å3, Z = 8, Rgt(F) = 0.0644, wRref(F2) = 0.1684, T = 100 K.

CCDC no.:: 1453239

The crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless, block Size 0.52 × 0.45 × 0.12 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:1.8 cm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
2θmax, completeness:74°, >99%
N(hkl)measured, N(hkl)unique, Rint:28135, 3251, 0.038
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 2913
N(param)refined:230
Programs:SHELX [24], Bruker programs [25]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
S10.87571(9)0.33935(6)0.80858(2)0.0325(3)
N10.8866(3)0.5665(2)0.81759(8)0.0268(6)
H1N10.895(3)0.626(3)0.8066(11)0.028(9)*
N20.8699(3)0.5019(2)0.74984(8)0.0332(7)
N30.8784(3)0.5489(2)0.66160(7)0.0297(6)
C10.9991(3)0.5098(2)0.88485(8)0.0220(6)
H1A1.08490.53600.87360.026*
H1B0.99100.42880.87920.026*
C20.9947(3)0.5311(2)0.93243(8)0.0213(6)
H2A1.06890.48920.94580.026*
C31.0100(3)0.6581(2)0.94189(9)0.0229(6)
H3A1.09630.68550.93140.027*
H3B1.00740.67060.97190.027*
C40.8941(3)0.7228(2)0.92086(8)0.0206(6)
H4A0.90370.80460.92640.025*
C50.8988(3)0.7016(2)0.87356(9)0.0235(6)
H5A0.98480.72800.86250.028*
H5B0.82710.74450.86000.028*
C60.8816(3)0.5742(2)0.86386(8)0.0185(6)
C70.7454(3)0.5332(2)0.88128(8)0.0195(6)
H7A0.73350.45280.87530.023*
H7B0.67190.57490.86810.023*
C80.7431(3)0.5532(2)0.92892(8)0.0218(6)
H8A0.65670.52610.94030.026*
C90.7582(3)0.6812(2)0.93783(9)0.0239(6)
H9A0.68490.72280.92460.029*
H9B0.75360.69480.96770.029*
C100.8599(3)0.4885(2)0.94976(8)0.0221(6)
H10A0.85700.50020.97980.026*
H10B0.85070.40740.94440.026*
C110.8780(3)0.4761(3)0.79153(9)0.0279(7)
C120.9169(5)0.4153(3)0.71935(10)0.0501(11)
H12A0.89370.33980.72940.060*
H12B1.01470.41950.71670.060*
C130.8520(4)0.4345(3)0.67681(9)0.0381(9)
H13A0.88770.37940.65700.046*
H13B0.75490.42270.67890.046*
C140.8242(4)0.6309(3)0.69110(9)0.0343(8)
H14A0.72650.62190.69240.041*
H14B0.84290.70710.68080.041*
C150.8803(4)0.6202(3)0.73424(9)0.0336(8)
H15A0.97460.64340.73420.040*
H15B0.83110.67070.75290.040*
C160.8728(3)0.5705(2)0.61828(8)0.0190(6)
C170.8895(3)0.6817(2)0.60288(9)0.0221(6)
H17A0.89900.74200.62160.026*
C180.8921(3)0.7028(3)0.56024(9)0.0232(6)
H18A0.90240.77730.55080.028*
C190.8798(3)0.6152(3)0.53140(8)0.0227(6)
H19A0.88170.62990.50280.027*
C200.8643(3)0.5047(3)0.54633(8)0.0222(6)
H20A0.85710.44460.52750.027*
C210.8595(3)0.4825(2)0.58882(8)0.0205(6)
H21A0.84720.40800.59800.025*

Source of material

A mixture of 1-adamantyl isothiocyanate (1.93 g, 0.01 mol) and 1-phenylpiperazine (1.62 g, 0.01 mol) in ethanol (20 mL), was heated under reflux for two hours. On cooling, the precipitated crude product was filtered, washed with cold ethanol, dried, and crystallized from ethanol to yield 3.24 g (91%) of the title compound (C21H29N3S) as colourless block crystals. M.P.: 447–449 K. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of a solution of the title compound in EtOH/CHCl3 (2:1) at room temperature. 1H NMR (DMSO-d6, 500.13 MHz): δ 1.63 (s, 6H, Adamantane-H), 1.96–2.05 (s, 3H, Adamantane-H), 2.27 (s, 6H, Adamantane-H), 3.16–3.20 (m, 4H, Piperazine-H), 3.84–3.88 (m, 4H, Piperazine-H), 6.64 (s, 1H, NH), 6.77–6.80 (m, 1H, Ar—H), 6.92–6.94 (m, 2H, Ar—H), 7.21–7.24 (m, 2H, Ar—H). 13C NMR (DMSO-d6, 125.76 MHz): δ 29.08, 36.08, 40.90, 46.96 (Adamantane-C), 47.66, 53.80 (Piperazine-C), 115.15, 118.82, 128.95, 150.48 (Ar—C), 180.41 (C = S). ESI-MS, m/z: 356.4 (M+H)+.

Experimental details

Carbon-bound H atoms were placed in calculated positions (C—H 0.93 Å) and were included in the refinement in the riding model approximation, with Uiso(H) set to 1.2Ueq(C). The nitrogen-bound H atoms was located on a difference Fourier map and refined freely.

Discussion

Adamantane derivatives were early known for their diverse pharmacological activities [1]. Several adamantyl-bearing analogues are currently employed as potent medications for the control of viral infections [2–5], hyperglycemia [6] and central nervous disorders [7, 8]. In addition, numerous adamantane derivatives were reported to exhibit potent anticancer [9, 10], bactericidal, fungicidal [11, 12] and antimalarial [13] activities. Moreover, various N-(1- and 2-adamantyl)carboxamides and N-(substituted)carbothioamides were reported to display diverse pharmacological activities [14–17]. As a part of our ongoing research interest in the chemotherapeutic [18–21] and structural [22, 23] properties of adamantane derivatives, we recently reported the synthesis, antibacterial and hypoglycemic activities of the title compound [21], and we report herein its crystal structure.

The crystal structure of the title compound, C17H22N2S, contains one molecule in the asymmetric unit. All bond lengths and angles are in the expected ranges. The central piprazine ring (N2—C12—C13—N3—C14—C15) has the typical chair conformation. In the crystal structure, molecules are connected at least by one intermolecular hydrogen bond, of which S1 works as hydrogen bond acceptor and C5 works as hydrogen bond donor (Symmetry code: −x+3/2, y−1/2, z).

The NH group (N1) is not involved in any hydrogen bonding interaction, as this group is shielded by two adjacent CH2 groups.

Acknowledgements:

This research project was supported by a grant from the Research Center of the Female Scientific and Medical Colleges, Deanship of Scientific Research, King Saud University.

References

1. Lamoureux, G.; Artavia, G.: Use of the adamantane structure in medicinal chemistry. Curr. Med. Chem. 17 (2010) 2967–2978.10.2174/092986710792065027Search in Google Scholar

2. Rabinovich, S.; Baldini, J. T.; Bannister, R.: Treatment of influenza. The therapeutic efficacy of rimantadine HCl in a naturally occurring influenza A2 outbreak. Am. J. Med. Sci. 257 (1969) 328–335.10.1097/00000441-196905000-00005Search in Google Scholar

3. Davies, W. L.; Grunnert, R. R.; Haff, R. F.; McGahen, J. W.; Neumeyer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E.: Antiviral activity of 1-adamantamine (amantadine). Science 144 (1964) 862–863.10.1126/science.144.3620.862Search in Google Scholar

4. Hayden, F. G.; Gwaltney, J. M. I.; Van, C. R. L.; Adams, K. F.; Giordani, B.: Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob. Agents Chemother. 19 (1981) 226–233.10.1128/AAC.19.2.226Search in Google Scholar

5. Rosenthal, K. S.; Sokol, M. S.; Ingram, R. L.; Subramanian, R.; Fort, R. C.: Tromantadine: Inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22 (1982) 1031–1036.10.1128/AAC.22.6.1031Search in Google Scholar

6. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E.: 1-(3-Hydroxy-1-adamantyl)aminoacetyl-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 46 (2003) 2774–2789.10.1021/jm030091lSearch in Google Scholar

7. Bormann, J.: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166 (1989) 591–592.10.1016/0014-2999(89)90385-3Search in Google Scholar

8. Abou-Gharbia, M. A.; Childers, W. E.; Fletcher, H.; McGaughey, G.; Patel, U.; Webb, M. B.; Yardley, J.; Andree, T.; Boast, C.; Kucharik, R. J.; Marquis, K.; Morris, H.; Scerni, R.; Moyer, J. A.: Synthesis and SAR of adatanserin: Novel adamantly aryl- and heteroarylpiperazines with dual serotonin 5-HT1Aand 5-HT2 activity as potential anxiolytic and antidepressant agents. J. Med. Chem. 42 (1999) 5077–5094.10.1021/jm9806704Search in Google Scholar PubMed

9. Sun, S. Y.; Yue, P.; Chen, X.; Hong, W. K.; Lotan, R.: The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. 62 (2002) 2430–2436.Search in Google Scholar

10. Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lira, Á. R.: Inhibition of IκB kinase-β and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 51 (2008) 5431–5440.10.1021/jm800285fSearch in Google Scholar PubMed

11. Jia, L.; Tomaszewski, J. E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M.: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Brit. J. Pharmacol. 144 (2005) 80–87.10.1038/sj.bjp.0705984Search in Google Scholar PubMed PubMed Central

12. Omar, K.; Geronikaki, A.; Zoumpoulakis, P.; Camoutsis, C.; Soković, M.; Ćirić, A.; Glamoćlija, J.: Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg. Med. Chem. 18 (2010) 426–432.10.1016/j.bmc.2009.10.041Search in Google Scholar PubMed

13. Wang, X.; Dong, Y.; Wittlin, S.; Charman, S. A.; Chiu, F. C. K.; Chollet, J.; Katneni, K.; Mannila, J.; Morizzi, J.; Ryan, E.; Scheurer, C.; Steuten, J.; Tomas, J. S.; Snyder, C.; Vennerstrom, J. L.: Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres. J. Med. Chem. 56 (2013) 2547–2555.10.1021/jm400004uSearch in Google Scholar PubMed

14. Cheng, H.; Hoffman, J.; Le, P.; Nair, S. K.; Cripps, S.; Matthews, J.; Smith, C.; Yang, M.; Kupchinsky, S.; Dress, K.; Edwards, M.; Cole, B.; Walters, E.; Loh, C.; Ermolieff, J.; Fanjul, A.; Bhat, G. B.; Herrera, J.; Pauly, T.; Hosea, N.; Paderes, G.; Rejto, P.: The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 20 (2010) 2897–2902.10.1016/j.bmcl.2010.03.032Search in Google Scholar PubMed

15. Joubert, J.; van Dyk, S.; Green, I. R.; Malan, S. F.: Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents. Bioorg. Med. Chem. 19 (2011) 3935–3944.10.1016/j.bmc.2011.05.034Search in Google Scholar PubMed

16. Malik, S.; Bahare, R. S.; Khan, S. A.: Design, synthesis and anticonvulsant evaluation of N-(benzo[b]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: A hybrid pharmacophore approach. Eur. J. Med. Chem. 67 (2013) 1–13.10.1016/j.ejmech.2013.06.026Search in Google Scholar PubMed

17. Zhu, S.-L.; Wu, Y.; Liu, C.-J.; Wei, C.-Y.; Tao, J.-C.; Liu, H.-M.: Synthesis and in vitro cytotoxic activity evaluation of novel heterocycle bridged carbothioamide type derivatives as antitumor agents. Bioorg. Med. Chem. Lett. 23 (2013) 1343–1346.10.1016/j.bmcl.2012.12.091Search in Google Scholar PubMed

18. El-Emam, A. A.; Al-Deeb, O. A.; Al-Omar, M. A.; Lehmann, J.: Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107–5113.10.1016/j.bmc.2004.07.033Search in Google Scholar PubMed

19. El-Emam, A. A.; Al-Tamimi, A.-M. S.; Al-Omar, M. A.; Al-Rashood, K. A.; Habib, E. E.: Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones. Eur. J. Med. Chem. 68 (2013) 96–102.10.1016/j.ejmech.2013.07.024Search in Google Scholar PubMed

20. Kadi, A. A.; Al-Abdullah, E. S.; Shehata, I. A.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial and anti-inflammatory activities of novel 5-(1-adamantyl)-1,3,4-thiadiazole Derivatives. Eur. J. Med. Chem. 45 (2010) 5006–5011.10.1016/j.ejmech.2010.08.007Search in Google Scholar PubMed

21. Al-Abdullah, E. S.; Al-Tuwaijri, H. M.; Hassan, H. M.; Al-Alshaikh, M. A.; Habib, E. E.; El-Emam, A. A.: Synthesis, antimicrobial and hypoglycemic activities of novel N-(1-adamanty)carbothioamide derivatives. Molecules 20 (2015) 8125–8143.10.3390/molecules20058125Search in Google Scholar PubMed PubMed Central

22. Al-Omary, F. A. M.; Mary, Y. S.; Panicker, C. Y.; El-Emam, A. A.; Al-Swaidan, I. A.; Al-Saadi, A. A.; Van Alsenoy, C.: Spectroscopic investigations, NBO, HOMO-LUMO, NLO analysis and molecular docking of 5-(adamantan-1-yl)-3-anilinomethyl-2,3-dihydro-1,3,4-oxadiazole-2-thione, a potential bioactive agent. J. Mol. Struct. 1096 (2015) 1–14.10.1016/j.molstruc.2015.03.049Search in Google Scholar

23. Al-Tamimi, A.-M. S.; El-Emam, A. A.; Al-Deeb, O. A.; Prasad, O.; Pathak, S. K.; Srivastava, R.; Sinha, L.: Structural and spectroscopic characterization of a novel potential anti-inflammatory agent 3-(adamantan-1-yl)-4-ethyl-1H-1,2,4-triazole-5(4H)thione by first principle calculations. Spectrochim. Acta A 124 (2014) 108–123.10.1016/j.saa.2013.12.103Search in Google Scholar PubMed

24. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

25. Bruker. APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA, 2009.Search in Google Scholar

Received: 2016-2-14
Accepted: 2016-4-20
Published Online: 2016-5-19
Published in Print: 2016-9-1

©2016 Ebtehal S. Al-Abdullah et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Articles in the same Issue

  1. Frontmatter
  2. Crystal structure of poly[aqua(μ2-2,5-bis(4-pyridyl)-1,3,4-oxadiazole-κ2N,N)(μ2-1,3-phenylenediacetato-κ3O,O′:O′′)cobalt(II)], C22H18CoN4O6
  3. Crystal structure of 2-amino-7,7-dimethyl-5-oxo-4-(3-phenoxy-phenyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
  4. Crystal structure of (E)-4,4′-(diazene-1,2-diyl)bis(1-nitro-1H-1,2,4-triazol-5(4H)-one)—acetonitrile (1:1), C6H5N11O6
  5. Crystal structure of potassium (E)-5-oxo-4-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)diazenyl)-4,5-dihydro-1,2,4-triazol-1-ide – (E)-4,4-diazene-1,2-diylbis(2,4-dihydro-3H-1,2,4-triazol-3-one) – methanol (1/1/1), C9H11N16KO5
  6. Crystal structure of (N,N′-bis(2-(((2,6-diisopropylphenyl)imino)methyl)phenyl)benzene-1,2-diamido-κ4O,O′,O′′,O′′′)oxidovanadium(IV), C44H48N4OV
  7. Crystal structure of 5,5-bis(4-iodophenyl)-5H-cyclopenta[2,1-b:3,4-b′]dipyridine, C23H14I2N2
  8. Crystal structure of aquadichloridobis(1-((2-methyl-1H-imidazol-1-yl)methyl)-1H-benotriazole-κN)mercury(II), C22H24Cl2HgN10O
  9. Crystal structure of 2-[4-(1H-imidazol-1-yl)phenyl]-1H-benzimidazol-3-ium [2-(carboxymethyl)phenyl]acetate monohydrate, C26H24N4O5
  10. Crystal structure of 4,4′-bipiperidinium dichloride 0.12 hydrate, C10H22N2Cl2 · 0.12 H2O
  11. Crystal structure of catena-poly[tetraaqua(μ2-4,4′(E)-ethene-1,2-diyldipyridine-κ2N:N′)nickel(II)] bis(6-methyl-2-oxo-1,2-dihydro-pyridine-4-carboxylate) pentahydrate, C26H42N4O15Ni
  12. Crystal structure of ethyl-5-amino-1-(2,4-dinitrophenyl)-1H-pyrazole-4-carboxylate, C12H11N5O6
  13. Crystal structure of dicarbonyl(pyridin-2-olate-1-oxido-κ2O,O′)rhodium(I), C7H4NO4Rh
  14. Crystal structure of 1-(adamantan-1-yl)-3-(4-chlorophenyl)thiourea, C17H21ClN2S
  15. Crystal structure of 2-((2-chloropyridin-3-ylamino)methylene)malononitrile, C9H5ClN4
  16. Crystal structure of tetraaquabis(μ2-4-chlorobenzoato-κ2O:O,O′)bis(4-chlorobenzoato-κO)bis(1,10-phenanthroline-κ2N,N′)distrontium(II), C52H40Cl4N4O12Sr2
  17. Crystal structure of 3-hydroxy-3-phenyl-1,3-dihydro-2H-indol-2-one, C14H11NO2
  18. Crystal structures of bis(1,10-phenanthrolin-1-ium) aquapentakis(nitrato-κ2O,O′)neodym(III) monohydrate, C24H22N9NdO17
  19. Crystal structure of 2-ethyl-1-tert-butyl 3-oxo-2-[phenyl(tert-butoxycarbonylamino)methyl]-1,2-pyrrolidinedicarboxylate, C24H34N2O7
  20. Crystal structure of poly[diaquabis(μ4-benzene-1,3,5-tricarboxylato-κO1,κO2:κO3,κO4:κO5:κO6)-bis(μ2-4,4′-benzene-1,3-diylbis(4H-1,2,4-triazole-κ2N:N′)tricadmium(II)] tetrahydrate, C38H34Cd3N12O18
  21. Crystal structure of trans-dichlorido[1,3-bis(9-methyl-9H-fluoren-9-yl) benzimidazol-2-ylidene](pyridine)palladium(II) – a compound with anagostic CH–Pd interactions, C40H31Cl2N3Pd
  22. Crystal structure of catena-poly[(μ3-5-(4-(tetrazol-1-id-5-yl)phenoxy)benzene-1,3-dicarboxyato-κ3O:O′:N)(4-(3-(pyridin-4-yl)propyl)pyridinium-κN)zinc(II)], C28H22ZnN6O5
  23. Crystal structure of 3,6-di-2-pyridinyl-4-pyridazine carbonitrile, C15H9N5
  24. Crystal structure of 5,5,9,13-tetramethyltetracyclo[10·2·1·01,10·04,9]pentadecane-3,7,14-triol, C20H34O4
  25. Crystal structure of 2-amino-7-methyl-5-oxo-4-phenyl-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H12N2O3
  26. Crystal structure of the poly[(1,10-phenanthroline-κ2N,N′)(μ3-carboxylatophenoxyacetato-κ4O,O′:O′′;O′′′)lead(II)] monohydrate, C21H16N2O6Pb
  27. Crystal structure of the poly[(μ4-biphenyl-4,4′-dicarboxylato-κ4O:O′:O′′:O′′′) bis(μ3-8-(11-(oxysulfonyl)-4-silbenyl)-2-(oxysulfonyl)stilbene-κ4O:O′:O′′,O′′′) bis(1,10-phenanthroline-k2N,N′) dipraseodymium(III)], C94H64N4O16Pr2S4
  28. Crystal structure of 3-iodo-5-methoxy-7-(methoxymethoxy)-4-(3-methoxyphenoxy)-2H-chromen-2-one, C19H17IO7
  29. Crystal structure of poly[(5-carboxy-2,6-dimethylpyridinium-3-carboxylato-κO)tris(μ2-2,6-dimethylpyridinium-3,5-dicarboxylato-κ3O,O′:O′′)erbium(III)], C36H33ErN4O16
  30. This molecule targets at type 2 diabetes - a single crystal study on (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl] tetrahydro-2H-pyran-3-amine (Omarigliptin), C17H20F2N4O3S
  31. Crystal structure of poly[(μ2-2,2′-benzene-1,2-diyldiacetato-κ2O:O′), (μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N′)zinc(II)], C22H19N5O4Zn
  32. Crystal structure of tetraaqua(μ2-3-(3,5-dicarboxyphenoxy)benzene-1,2-dicarboxylato-κ2O:O′)manganese(II) dihydrate, C16H20O15Mn
  33. Crystal structure of 4,4′-sulfonyldipyridine, C10H8N2O2S
  34. Crystal structure of 4-[(E)-(2-chloro-6-fluorobenzylidene)amino]-1,2-dihydro-2,3-dimethyl-1-phenylpyrazol-5-one, C18H15ClFN3O
  35. Crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-κ2O, O′)(triphenylphosphine-κP)rhodium(I), C24H19NO3PRh
  36. Crystal structure of diaquabis(2-(3-bromophenyl)-5-carboxy-1H-imidazol-4-carboxylato-κ2O,N) cobalt(II) trihydrate, C22H22Br2CoN4O13
  37. Crystal structure of 4-(pyridin-4-ylmethylsulfonyl)pyridine, C11H10N2O2S
  38. Crystal structure of poly[(μ4-1-methyl-1H-tetrazole-5-thiolato-κ3S:S:N:N′)copper(I)], C2H3CuN4S
  39. Crystal structure of poly[diaquabis(μ2-4,4′-sulfinyldipyridine-κ2N,N′)zinc(II)] diperchlorate dihydrate, C20H24N4O14S2Cl2Zn
  40. Crystal structure of (1-((1-benzylpyrrolidin-2-yl-κN)methyl)-3-isopropyl-1H-imidazol-2(3H)-ylidene–κC)dibromidopalladium(II), C18H25Br2N3Pd
  41. Crystal structure of pentacalcium tetranitridovanadate(V) mononitride based on a powder diffraction study, Ca5[VN4]N
  42. Crystal structure of ((1-((1-benzylpyrrolidin-2-yl)methyl)-3-ethyl-1H-imidazol-2(3H)-ylidene)-κ2C,N)dichloridopalladium(II), C17H23Cl2N3Pd
  43. Crystal structure of 9-allyl-4,5-dichloro-12-cyano-9,10-dihydro-9,10-ethanoanthracen-12-yl acetate, C22H17Cl2NO2
  44. Crystal structure of 4-bromo-2-(8-(3-ethoxy-2-hydroxyphenyl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl)phenol, C18H19BrN2O5
  45. Crystal structure of 3-tert-butyl-3-hydroxy-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one, C11H14N2O2
  46. Crystal structure of diaquabis(3-(3,5-dibromophenyl)-5-(pyridin-2-yl)-1,2,4-triazol-4-ido-κ2N,N′)nickel(II) mono hydrate, C26H20Br4N8NiO3
  47. Crystal structure of 5-(adamantan-1-yl)-3-[(2-trifluoromethylanilino)methyl]-2,3-dihydro-1,3,4-oxadiazole-2-thione, C20H22F3N3OS
  48. Crystal structure of 2-ethyl-1-tert-butyl-2-((4-fluorophenyl)(tert-butoxycarbonylamino)methyl)-3-oxo-pyrrolidine-1,2-dicarboxylate, C24H33FN2O7
  49. Crystal structure of bis(μ2-2-fluorobenzoato-κ2O:O:O′) bis(μ2-2-fluorobenzoato-κ2O:O′)dinitrato-κ2O,O′ bis(1,10-phenathroline-κ2N,N′)diterbium(III), C52H32F4N6O14Tb2
  50. Crystal structure of tetrabutylammonium 4-aminobenzenesulfonate 2/3 hydrate, C22H42N2O3S · 2/3 H2O
  51. Crystal structure of tetraethylammonium 4-aminobenzenesulfonate, C14H26N2O3S
  52. Crystal structure of bis(guanidinium) 3,3′-oxybis(6-carboxybenzoate), C18H20N6O9
  53. Crystal structure of N′-(4-methoxybenzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C18H16N4O2
  54. Crystal structure of N′-(4-nitrobenzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C17H13N5O3
  55. Crystal structure of 5-((4-bromophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl)-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, C19H19BrN2O5
  56. Crystal structure of 3-(((cyclohexyl(phenyl)methylidene)amino)oxy)-2-hydroxy-N-(propan-2-yl)propan-1-aminium chloride, C19H31ClN2O2
  57. Crystal structure of 6-hydroxy-5-((2-hydroxy-6-oxocyclohex-1-en-1-yl)(phenyl)methyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, C19H20N2O5
  58. Crystal structure of 2-(4-(4-bromophenyl)thiazol-2-yl)isoindoline-1,3-dione, C17H9BrN2O2S
  59. Crystal structure of 2-(4-methylbenzoyl)pyrene, C24H16O
  60. Crystal structure of N-(5-bromo-4-(p-tolyl)thiazol-2-yl)-4-chlorobutanamide, C14H14BrClN2OS
  61. Crystal structure of 4,5-diphenylthiazol-2-amine, C15H12N2S
  62. Crystal structure of poly[bis(μ2-4-(3-(pyridin-3-yl)-1H-1,2,4-triazol-5-yl)benzoato-κ3N:O,O′)-lead(II)], C28H18O4N8Pb
  63. Crystal structure of (Z)-4-(4-oxopent-2-en-2-ylamino)benzenesulfonamide, C11H14N2O3S
  64. Crystal structure of poly[(μ2-2-methyl-1-(4-(2-methyl-2H-benzo[d] imidazol-1(7aH)-yl)butyl)-1H-benzo[d]imidazole-κ2N:N′)bis(μ3-5-tert-butylbenzene-1,3-dicarboxylato-κ4O:O,O′:O′′,O′′′)dicadmium(II)] tetrahydrate, C44H54Cd2N4O12
  65. Crystal structure of catena-poly-[aqua(μ2-4,4′-bipyridine-κ2N:N′)bis(3′,5,5′-tricarboxybiphenyl-2-carboxylato-κ2O,O′)cadmium(II)], C42H28N2O17Cd
  66. Crystal structure of (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol, C15H20ClN3O
  67. Crystal structure of N′-(4-(dimethylamino)benzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C19H19N5O
  68. Crystal structure of 3-(benzofuran-2-yl)-5-(4-fluorophenyl)-4,5-dihydro-1Hpyrazole-1-carbothioamide, C18H14FN3OS
  69. Crystal structure of ent-1β-acetoxy-7α,14α-di-hydroxy-7β,20-epoxykaur-16-en-15-one, C22H30O6
  70. Crystal structure of 1α,7β-dihydroxy-11β-acetoxy-ent-7β,20-epoxykaur-16-en-15-one, C22H30O6
  71. Crystal structure of 7β,14β,15β-trihydroxy-1α-acetoxy-7α,20-epoxy-ent-kaurane, C22H32O6
  72. Crystal structure of ent-1β,7α,11α-trihydroxy-7β,20-epoxykaur-16-en-15-one, C20H28O5
  73. Crystal structure of poly-[tetraaquabis(μ8-benzene-1,2,4,5-tetracarboxylato-1κ3O4:O6:O8:2κ4O2:O2:O5:O5:3κ4O1:O3:O5:O7)(di-μ3-hydroxido)-pentazinc(II)] decahydrate, C20H34O32Zn5
  74. Crystal structure of 1-(4-methylthiazol-2-yl)-3-propylthiourea, C8H13N3S2
  75. Crystal structure of 2-((dimethylamino)methylene)-5,5-Dimethylcyclohexane-1,3-dione, C11H17NO2
  76. Crystal structure of poly[1,4-bis(2-methylbenzimidazol)butane-κ2N:N′)bis(4,4′-oxybis(benzoato-κ4O,O′:O′′,O′′′)dicadmium] monohydrate, C48H38Cd2N4O10
  77. Crystal structure of 2-(3-(benzofuran-2-yl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole, C26H17ClFN3OS
  78. Crystal structure of bis(μ3-isophthalato-κ3O:O′:O′′)(μ2-1,4-\ bis((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)dizinc(II), C22H19N2O4Zn
  79. Crystal structure of poly[bis(adipate-κ4O,O′:O′′, O′′′)(1,4-bis(2-methyl-1H-benzo[d]imidazol-1-yl)benzene-κ2N:N′)dizinc(II), C36H38N4O8Zn2
  80. Crystal structure of N-(2-(2-oxoindolin-4-yl)ethyl)-N-propylpropan-1-aminium tetraphenylborate, C40H45BN2O
  81. Crystal structure of 1-(2,3-dihydro-4-methyl-3-phenyl-2-thioxothiazol-5-yl)-1-ethanone, C12H11NOS2
  82. Crystal structure of 3-(adamantan-1-yl)-1-[(4-benzylpiperazin-1-yl)methyl]-4-[(E)-(2,6-difluorobenzylidene)amino]-1H-1,2,4-triazole-5(4H)-thione, C31H36F2N6S
  83. Crystal structure of 6-(4-chlorophenyl)-3-(thiophen-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]-thiadiazole, C13H7ClN4S2
  84. Crystal structure of bis(ethanaminium) poly[bis(hexaselenido-κ2Se1,Se6)palladate(II)], C4H16N2PdSe12
  85. Crystal structure of 2-(3-(benzofuran-2-yl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole, C26H19N3OS
  86. Crystal structure of poly-[bis(μ3-5-hydroxyisophtalato-κ3O:O′:O′′)(μ2-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)dizinc(II)], C40H30N4O5Zn2
  87. Crystal structure of poly-[(μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ4-2,2′-(1,3-phenylene)diacetate-κ4O:O′:O′′:O′′′)dizinc(II)], C44H38N4O8Zn2
  88. Crystal structure of 5,17-bis-cyano-25,26,27,28-tetrapropyloxy-calix[4]arene, C42H46N2O4
  89. Crystal structure of poly-[μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ3-5-hydroxyisophthalate(2–)-κ3O,O′:O′′)dicadmium(II)] monohydrate, C64H54N8O11Cd2
  90. Crystal structure of poly-[μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ4-4,4′-sulfonyldibenzoato-κ4O:O′:O′′:O′′′)dicadmium(II)] monohydrate, C52H42N4O14Cd2
  91. Crystal structure of poly-[bis(μ4-adipato-κ4O:O′:O′′:O′′′)(μ2-1,4-bis((2-ethyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)dizinc(II)], C38H42N4O8Zn2
  92. Crystal structure of (2-(2-chlorophenyl)-5-methyl-1,3-dioxan-5-yl)methanol, C12H15ClO3
  93. Crystal structure of 2-(4-Bromophenyl)-5-ethyl-1,3-dioxane-5-carboxylic acid, C13H15BrO4
  94. Crystal structure of (2-(4-bromophenyl)-5-ethyl-1,3-dioxan-5-yl)methanol, C13H17BrO3
  95. Crystal structure of 3-((1,3,5,7-tetraoxo-6-(pyridin-3-ylmethyl)-3,3a,4,4a,5,6,7,7a,8,8a-decahydro-4,8-ethenopyrrolo[3,4-f]isoindol-2(1H)-yl)methyl)pyridin-1-ium-κN-trichloridocobalt(II) hemihydrate, C24H22Cl3CoN4O4.5
  96. Crystal structure of 4-chloro-4′,6′-dichloro-2,2′-[propane-1,3-diyldioxybis(nitrilomethylidyne)]-diphenol, C17H14Cl3N2O4
  97. Crystal structure of 2-amino-4-(3-trifluoromethylphenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C17H13F3N2O2
  98. Crystal structure of bis(benzoato-κO)bis(4,4′-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile-κN)zinc(II), C48H32N10O4Zn
  99. Crystal structure of 3-methyl-2H-chromen-2-one, C10H8O2
  100. Crystal structure of catena-poly-[aqua-(2-carboxy-5-(3-carboxy-5-carboxylatophenoxy)benzoato-κO)(μ2-4,4′-di(1H-imidazol-1-yl)-1,1′-biphenyl-κ2N:N′)cobalt(II)], C34H24N4O10Co
  101. Crystal structure of 4,4′-di(1H-imidazol-1-yl)-1,1′-biphenyl, C36H28N8
  102. Crystal structure of 1-(3-chloropropyl)piperidin-1-ium tetraphenylborate, C32H37BClN
  103. Crystal structure of dimethyl 5-(benzylamino)isophthalate, C17H17NO4
  104. Crystal structure of dimethyl 5-(dibenzylamino)isophthalate, C24H23NO4
  105. Crystal structure of N-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioamide, C21H29N3S
  106. Crystal structure of (2,2′(cyclohexane-1,2-diylbis(nitrilo(E)methylylidene))diphenolato-κ4O,O′,N,N′)dimethanolmanganese(III) bromide, C22H28BrMnN2O4
  107. Crystal structure of 3,5,7-tris(morpholinomethyl)tropolone·0.67 hydrate, C22H33N3O5·0.67H2O
  108. Crystal structure of biphenyl-2,3′,5,5′-tetracarboxylic acid – 4,4′-biphenyl-4,4′-diyldipyridine (3/2), C49H34N3O8
https://doi.org/10.1515/ncrs-2016-0056
Creative Commons
BY-NC-ND 3.0

Articles in the same Issue

  1. Frontmatter
  2. Crystal structure of poly[aqua(μ2-2,5-bis(4-pyridyl)-1,3,4-oxadiazole-κ2N,N)(μ2-1,3-phenylenediacetato-κ3O,O′:O′′)cobalt(II)], C22H18CoN4O6
  3. Crystal structure of 2-amino-7,7-dimethyl-5-oxo-4-(3-phenoxy-phenyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile
  4. Crystal structure of (E)-4,4′-(diazene-1,2-diyl)bis(1-nitro-1H-1,2,4-triazol-5(4H)-one)—acetonitrile (1:1), C6H5N11O6
  5. Crystal structure of potassium (E)-5-oxo-4-((5-oxo-1H-1,2,4-triazol-4(5H)-yl)diazenyl)-4,5-dihydro-1,2,4-triazol-1-ide – (E)-4,4-diazene-1,2-diylbis(2,4-dihydro-3H-1,2,4-triazol-3-one) – methanol (1/1/1), C9H11N16KO5
  6. Crystal structure of (N,N′-bis(2-(((2,6-diisopropylphenyl)imino)methyl)phenyl)benzene-1,2-diamido-κ4O,O′,O′′,O′′′)oxidovanadium(IV), C44H48N4OV
  7. Crystal structure of 5,5-bis(4-iodophenyl)-5H-cyclopenta[2,1-b:3,4-b′]dipyridine, C23H14I2N2
  8. Crystal structure of aquadichloridobis(1-((2-methyl-1H-imidazol-1-yl)methyl)-1H-benotriazole-κN)mercury(II), C22H24Cl2HgN10O
  9. Crystal structure of 2-[4-(1H-imidazol-1-yl)phenyl]-1H-benzimidazol-3-ium [2-(carboxymethyl)phenyl]acetate monohydrate, C26H24N4O5
  10. Crystal structure of 4,4′-bipiperidinium dichloride 0.12 hydrate, C10H22N2Cl2 · 0.12 H2O
  11. Crystal structure of catena-poly[tetraaqua(μ2-4,4′(E)-ethene-1,2-diyldipyridine-κ2N:N′)nickel(II)] bis(6-methyl-2-oxo-1,2-dihydro-pyridine-4-carboxylate) pentahydrate, C26H42N4O15Ni
  12. Crystal structure of ethyl-5-amino-1-(2,4-dinitrophenyl)-1H-pyrazole-4-carboxylate, C12H11N5O6
  13. Crystal structure of dicarbonyl(pyridin-2-olate-1-oxido-κ2O,O′)rhodium(I), C7H4NO4Rh
  14. Crystal structure of 1-(adamantan-1-yl)-3-(4-chlorophenyl)thiourea, C17H21ClN2S
  15. Crystal structure of 2-((2-chloropyridin-3-ylamino)methylene)malononitrile, C9H5ClN4
  16. Crystal structure of tetraaquabis(μ2-4-chlorobenzoato-κ2O:O,O′)bis(4-chlorobenzoato-κO)bis(1,10-phenanthroline-κ2N,N′)distrontium(II), C52H40Cl4N4O12Sr2
  17. Crystal structure of 3-hydroxy-3-phenyl-1,3-dihydro-2H-indol-2-one, C14H11NO2
  18. Crystal structures of bis(1,10-phenanthrolin-1-ium) aquapentakis(nitrato-κ2O,O′)neodym(III) monohydrate, C24H22N9NdO17
  19. Crystal structure of 2-ethyl-1-tert-butyl 3-oxo-2-[phenyl(tert-butoxycarbonylamino)methyl]-1,2-pyrrolidinedicarboxylate, C24H34N2O7
  20. Crystal structure of poly[diaquabis(μ4-benzene-1,3,5-tricarboxylato-κO1,κO2:κO3,κO4:κO5:κO6)-bis(μ2-4,4′-benzene-1,3-diylbis(4H-1,2,4-triazole-κ2N:N′)tricadmium(II)] tetrahydrate, C38H34Cd3N12O18
  21. Crystal structure of trans-dichlorido[1,3-bis(9-methyl-9H-fluoren-9-yl) benzimidazol-2-ylidene](pyridine)palladium(II) – a compound with anagostic CH–Pd interactions, C40H31Cl2N3Pd
  22. Crystal structure of catena-poly[(μ3-5-(4-(tetrazol-1-id-5-yl)phenoxy)benzene-1,3-dicarboxyato-κ3O:O′:N)(4-(3-(pyridin-4-yl)propyl)pyridinium-κN)zinc(II)], C28H22ZnN6O5
  23. Crystal structure of 3,6-di-2-pyridinyl-4-pyridazine carbonitrile, C15H9N5
  24. Crystal structure of 5,5,9,13-tetramethyltetracyclo[10·2·1·01,10·04,9]pentadecane-3,7,14-triol, C20H34O4
  25. Crystal structure of 2-amino-7-methyl-5-oxo-4-phenyl-4H,5H-pyrano[4,3-b]pyran-3-carbonitrile, C16H12N2O3
  26. Crystal structure of the poly[(1,10-phenanthroline-κ2N,N′)(μ3-carboxylatophenoxyacetato-κ4O,O′:O′′;O′′′)lead(II)] monohydrate, C21H16N2O6Pb
  27. Crystal structure of the poly[(μ4-biphenyl-4,4′-dicarboxylato-κ4O:O′:O′′:O′′′) bis(μ3-8-(11-(oxysulfonyl)-4-silbenyl)-2-(oxysulfonyl)stilbene-κ4O:O′:O′′,O′′′) bis(1,10-phenanthroline-k2N,N′) dipraseodymium(III)], C94H64N4O16Pr2S4
  28. Crystal structure of 3-iodo-5-methoxy-7-(methoxymethoxy)-4-(3-methoxyphenoxy)-2H-chromen-2-one, C19H17IO7
  29. Crystal structure of poly[(5-carboxy-2,6-dimethylpyridinium-3-carboxylato-κO)tris(μ2-2,6-dimethylpyridinium-3,5-dicarboxylato-κ3O,O′:O′′)erbium(III)], C36H33ErN4O16
  30. This molecule targets at type 2 diabetes - a single crystal study on (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl] tetrahydro-2H-pyran-3-amine (Omarigliptin), C17H20F2N4O3S
  31. Crystal structure of poly[(μ2-2,2′-benzene-1,2-diyldiacetato-κ2O:O′), (μ2-1-(4-(1H-imidazol-1-yl)benzyl)-1H-1,2,4-triazole-κ2N:N′)zinc(II)], C22H19N5O4Zn
  32. Crystal structure of tetraaqua(μ2-3-(3,5-dicarboxyphenoxy)benzene-1,2-dicarboxylato-κ2O:O′)manganese(II) dihydrate, C16H20O15Mn
  33. Crystal structure of 4,4′-sulfonyldipyridine, C10H8N2O2S
  34. Crystal structure of 4-[(E)-(2-chloro-6-fluorobenzylidene)amino]-1,2-dihydro-2,3-dimethyl-1-phenylpyrazol-5-one, C18H15ClFN3O
  35. Crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-κ2O, O′)(triphenylphosphine-κP)rhodium(I), C24H19NO3PRh
  36. Crystal structure of diaquabis(2-(3-bromophenyl)-5-carboxy-1H-imidazol-4-carboxylato-κ2O,N) cobalt(II) trihydrate, C22H22Br2CoN4O13
  37. Crystal structure of 4-(pyridin-4-ylmethylsulfonyl)pyridine, C11H10N2O2S
  38. Crystal structure of poly[(μ4-1-methyl-1H-tetrazole-5-thiolato-κ3S:S:N:N′)copper(I)], C2H3CuN4S
  39. Crystal structure of poly[diaquabis(μ2-4,4′-sulfinyldipyridine-κ2N,N′)zinc(II)] diperchlorate dihydrate, C20H24N4O14S2Cl2Zn
  40. Crystal structure of (1-((1-benzylpyrrolidin-2-yl-κN)methyl)-3-isopropyl-1H-imidazol-2(3H)-ylidene–κC)dibromidopalladium(II), C18H25Br2N3Pd
  41. Crystal structure of pentacalcium tetranitridovanadate(V) mononitride based on a powder diffraction study, Ca5[VN4]N
  42. Crystal structure of ((1-((1-benzylpyrrolidin-2-yl)methyl)-3-ethyl-1H-imidazol-2(3H)-ylidene)-κ2C,N)dichloridopalladium(II), C17H23Cl2N3Pd
  43. Crystal structure of 9-allyl-4,5-dichloro-12-cyano-9,10-dihydro-9,10-ethanoanthracen-12-yl acetate, C22H17Cl2NO2
  44. Crystal structure of 4-bromo-2-(8-(3-ethoxy-2-hydroxyphenyl)-3,6-dioxa-2,7-diazaocta-1,7-dien-1-yl)phenol, C18H19BrN2O5
  45. Crystal structure of 3-tert-butyl-3-hydroxy-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one, C11H14N2O2
  46. Crystal structure of diaquabis(3-(3,5-dibromophenyl)-5-(pyridin-2-yl)-1,2,4-triazol-4-ido-κ2N,N′)nickel(II) mono hydrate, C26H20Br4N8NiO3
  47. Crystal structure of 5-(adamantan-1-yl)-3-[(2-trifluoromethylanilino)methyl]-2,3-dihydro-1,3,4-oxadiazole-2-thione, C20H22F3N3OS
  48. Crystal structure of 2-ethyl-1-tert-butyl-2-((4-fluorophenyl)(tert-butoxycarbonylamino)methyl)-3-oxo-pyrrolidine-1,2-dicarboxylate, C24H33FN2O7
  49. Crystal structure of bis(μ2-2-fluorobenzoato-κ2O:O:O′) bis(μ2-2-fluorobenzoato-κ2O:O′)dinitrato-κ2O,O′ bis(1,10-phenathroline-κ2N,N′)diterbium(III), C52H32F4N6O14Tb2
  50. Crystal structure of tetrabutylammonium 4-aminobenzenesulfonate 2/3 hydrate, C22H42N2O3S · 2/3 H2O
  51. Crystal structure of tetraethylammonium 4-aminobenzenesulfonate, C14H26N2O3S
  52. Crystal structure of bis(guanidinium) 3,3′-oxybis(6-carboxybenzoate), C18H20N6O9
  53. Crystal structure of N′-(4-methoxybenzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C18H16N4O2
  54. Crystal structure of N′-(4-nitrobenzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C17H13N5O3
  55. Crystal structure of 5-((4-bromophenyl)(2-hydroxy-6-oxocyclohex-1-en-1-yl)methyl)-6-hydroxy-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, C19H19BrN2O5
  56. Crystal structure of 3-(((cyclohexyl(phenyl)methylidene)amino)oxy)-2-hydroxy-N-(propan-2-yl)propan-1-aminium chloride, C19H31ClN2O2
  57. Crystal structure of 6-hydroxy-5-((2-hydroxy-6-oxocyclohex-1-en-1-yl)(phenyl)methyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, C19H20N2O5
  58. Crystal structure of 2-(4-(4-bromophenyl)thiazol-2-yl)isoindoline-1,3-dione, C17H9BrN2O2S
  59. Crystal structure of 2-(4-methylbenzoyl)pyrene, C24H16O
  60. Crystal structure of N-(5-bromo-4-(p-tolyl)thiazol-2-yl)-4-chlorobutanamide, C14H14BrClN2OS
  61. Crystal structure of 4,5-diphenylthiazol-2-amine, C15H12N2S
  62. Crystal structure of poly[bis(μ2-4-(3-(pyridin-3-yl)-1H-1,2,4-triazol-5-yl)benzoato-κ3N:O,O′)-lead(II)], C28H18O4N8Pb
  63. Crystal structure of (Z)-4-(4-oxopent-2-en-2-ylamino)benzenesulfonamide, C11H14N2O3S
  64. Crystal structure of poly[(μ2-2-methyl-1-(4-(2-methyl-2H-benzo[d] imidazol-1(7aH)-yl)butyl)-1H-benzo[d]imidazole-κ2N:N′)bis(μ3-5-tert-butylbenzene-1,3-dicarboxylato-κ4O:O,O′:O′′,O′′′)dicadmium(II)] tetrahydrate, C44H54Cd2N4O12
  65. Crystal structure of catena-poly-[aqua(μ2-4,4′-bipyridine-κ2N:N′)bis(3′,5,5′-tricarboxybiphenyl-2-carboxylato-κ2O,O′)cadmium(II)], C42H28N2O17Cd
  66. Crystal structure of (2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol, C15H20ClN3O
  67. Crystal structure of N′-(4-(dimethylamino)benzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C19H19N5O
  68. Crystal structure of 3-(benzofuran-2-yl)-5-(4-fluorophenyl)-4,5-dihydro-1Hpyrazole-1-carbothioamide, C18H14FN3OS
  69. Crystal structure of ent-1β-acetoxy-7α,14α-di-hydroxy-7β,20-epoxykaur-16-en-15-one, C22H30O6
  70. Crystal structure of 1α,7β-dihydroxy-11β-acetoxy-ent-7β,20-epoxykaur-16-en-15-one, C22H30O6
  71. Crystal structure of 7β,14β,15β-trihydroxy-1α-acetoxy-7α,20-epoxy-ent-kaurane, C22H32O6
  72. Crystal structure of ent-1β,7α,11α-trihydroxy-7β,20-epoxykaur-16-en-15-one, C20H28O5
  73. Crystal structure of poly-[tetraaquabis(μ8-benzene-1,2,4,5-tetracarboxylato-1κ3O4:O6:O8:2κ4O2:O2:O5:O5:3κ4O1:O3:O5:O7)(di-μ3-hydroxido)-pentazinc(II)] decahydrate, C20H34O32Zn5
  74. Crystal structure of 1-(4-methylthiazol-2-yl)-3-propylthiourea, C8H13N3S2
  75. Crystal structure of 2-((dimethylamino)methylene)-5,5-Dimethylcyclohexane-1,3-dione, C11H17NO2
  76. Crystal structure of poly[1,4-bis(2-methylbenzimidazol)butane-κ2N:N′)bis(4,4′-oxybis(benzoato-κ4O,O′:O′′,O′′′)dicadmium] monohydrate, C48H38Cd2N4O10
  77. Crystal structure of 2-(3-(benzofuran-2-yl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-(4-chlorophenyl)thiazole, C26H17ClFN3OS
  78. Crystal structure of bis(μ3-isophthalato-κ3O:O′:O′′)(μ2-1,4-\ bis((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)dizinc(II), C22H19N2O4Zn
  79. Crystal structure of poly[bis(adipate-κ4O,O′:O′′, O′′′)(1,4-bis(2-methyl-1H-benzo[d]imidazol-1-yl)benzene-κ2N:N′)dizinc(II), C36H38N4O8Zn2
  80. Crystal structure of N-(2-(2-oxoindolin-4-yl)ethyl)-N-propylpropan-1-aminium tetraphenylborate, C40H45BN2O
  81. Crystal structure of 1-(2,3-dihydro-4-methyl-3-phenyl-2-thioxothiazol-5-yl)-1-ethanone, C12H11NOS2
  82. Crystal structure of 3-(adamantan-1-yl)-1-[(4-benzylpiperazin-1-yl)methyl]-4-[(E)-(2,6-difluorobenzylidene)amino]-1H-1,2,4-triazole-5(4H)-thione, C31H36F2N6S
  83. Crystal structure of 6-(4-chlorophenyl)-3-(thiophen-2-yl)-[1,2,4]triazolo[3,4-b][1,3,4]-thiadiazole, C13H7ClN4S2
  84. Crystal structure of bis(ethanaminium) poly[bis(hexaselenido-κ2Se1,Se6)palladate(II)], C4H16N2PdSe12
  85. Crystal structure of 2-(3-(benzofuran-2-yl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazole, C26H19N3OS
  86. Crystal structure of poly-[bis(μ3-5-hydroxyisophtalato-κ3O:O′:O′′)(μ2-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)dizinc(II)], C40H30N4O5Zn2
  87. Crystal structure of poly-[(μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ4-2,2′-(1,3-phenylene)diacetate-κ4O:O′:O′′:O′′′)dizinc(II)], C44H38N4O8Zn2
  88. Crystal structure of 5,17-bis-cyano-25,26,27,28-tetrapropyloxy-calix[4]arene, C42H46N2O4
  89. Crystal structure of poly-[μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ3-5-hydroxyisophthalate(2–)-κ3O,O′:O′′)dicadmium(II)] monohydrate, C64H54N8O11Cd2
  90. Crystal structure of poly-[μ-1,4-bis(2-ethylbenzimidazol-1-ylmethyl)benzene-κ2N:N′)-bis(μ4-4,4′-sulfonyldibenzoato-κ4O:O′:O′′:O′′′)dicadmium(II)] monohydrate, C52H42N4O14Cd2
  91. Crystal structure of poly-[bis(μ4-adipato-κ4O:O′:O′′:O′′′)(μ2-1,4-bis((2-ethyl-1H-benzo[d]imidazol-1-yl)methyl)benzene-κ2N:N′)dizinc(II)], C38H42N4O8Zn2
  92. Crystal structure of (2-(2-chlorophenyl)-5-methyl-1,3-dioxan-5-yl)methanol, C12H15ClO3
  93. Crystal structure of 2-(4-Bromophenyl)-5-ethyl-1,3-dioxane-5-carboxylic acid, C13H15BrO4
  94. Crystal structure of (2-(4-bromophenyl)-5-ethyl-1,3-dioxan-5-yl)methanol, C13H17BrO3
  95. Crystal structure of 3-((1,3,5,7-tetraoxo-6-(pyridin-3-ylmethyl)-3,3a,4,4a,5,6,7,7a,8,8a-decahydro-4,8-ethenopyrrolo[3,4-f]isoindol-2(1H)-yl)methyl)pyridin-1-ium-κN-trichloridocobalt(II) hemihydrate, C24H22Cl3CoN4O4.5
  96. Crystal structure of 4-chloro-4′,6′-dichloro-2,2′-[propane-1,3-diyldioxybis(nitrilomethylidyne)]-diphenol, C17H14Cl3N2O4
  97. Crystal structure of 2-amino-4-(3-trifluoromethylphenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile, C17H13F3N2O2
  98. Crystal structure of bis(benzoato-κO)bis(4,4′-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile-κN)zinc(II), C48H32N10O4Zn
  99. Crystal structure of 3-methyl-2H-chromen-2-one, C10H8O2
  100. Crystal structure of catena-poly-[aqua-(2-carboxy-5-(3-carboxy-5-carboxylatophenoxy)benzoato-κO)(μ2-4,4′-di(1H-imidazol-1-yl)-1,1′-biphenyl-κ2N:N′)cobalt(II)], C34H24N4O10Co
  101. Crystal structure of 4,4′-di(1H-imidazol-1-yl)-1,1′-biphenyl, C36H28N8
  102. Crystal structure of 1-(3-chloropropyl)piperidin-1-ium tetraphenylborate, C32H37BClN
  103. Crystal structure of dimethyl 5-(benzylamino)isophthalate, C17H17NO4
  104. Crystal structure of dimethyl 5-(dibenzylamino)isophthalate, C24H23NO4
  105. Crystal structure of N-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioamide, C21H29N3S
  106. Crystal structure of (2,2′(cyclohexane-1,2-diylbis(nitrilo(E)methylylidene))diphenolato-κ4O,O′,N,N′)dimethanolmanganese(III) bromide, C22H28BrMnN2O4
  107. Crystal structure of 3,5,7-tris(morpholinomethyl)tropolone·0.67 hydrate, C22H33N3O5·0.67H2O
  108. Crystal structure of biphenyl-2,3′,5,5′-tetracarboxylic acid – 4,4′-biphenyl-4,4′-diyldipyridine (3/2), C49H34N3O8
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 16.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0056/html?srsltid=AfmBOoqfBAe6nYsJWqSlgHPWyOTQlu9lWhLlUSv8nw31DDAZo1BSeXkE
Scroll to top button